A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic
Mohsen Gholi-Nataj1, Shahab Rafieian2, Maedeh Barahman3, Ahmad Shirinzadeh-Dastgiri4, Mohammad Vakili5, Reza Ershadi61Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran, 2Department of Thoracic Surgery, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran, 3Firoozgar Clinical Research Development Center (FCRDC), Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran, 4Department of Surgery, Faculty of Medicine, Shohadaye Hafte-e-tie hospital, Iran University of Medical Sciences, Tehran, Iran, 5Department of Surgery, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran, 6Department of Thoracic Surgery, Valiasr Hospital, Tehran University of Medical Sciences, Tehran, Iran,
Objectives: Cancer patients were found to be at higher risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and experienced more adverse outcomes. The objective of this meta-analysis was to estimate the prevalence of lung cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic. Methods: A comprehensive search was carried out on PubMed, Web of Science, Scopus, MedRxiv, SciELO, SID, CNKI, and Wanfang databases to retrieve all relevant publications. All cross-sectional studies and consecutive case series on cancer patients with SARS-CoV-2 infection were selected. A total of 28 studies including 5400 infected cancer patients and 767 lung cancer patients with COVID-19 were included. Results: Combined data indicated that the prevalence of lung cancer patients with SARS-CoV-2 infection was 15.2% (95% CI, 0.111–0.205) overall. Stratified analysis by ethnicity showed that the prevalence was 16.4% and 15.4% in Asian and Caucasian lung cancer patients with COVID-19, respectively. Moreover, subgroup analysis by country of origin showed that the prevalence was highest in China (19.3.0%) followed by France (12.6%), the UK (10.7%), and the USA (8.3%). Conclusion: This meta-analysis revealed that the prevalence of lung cancer patients with SARS-CoV-2 infection during the COVID-19 pandemic was 15.2%. Keywords: SARS-CoV-2, COVID-19, Lung cancer, Infection, Meta-analysis
Cite This Article
Gholi-Nataj M, Rafieian S, Barahman M, Shirinzadeh-Dastgiri A, Vakili M, Ershadi R. A Meta-analysis for Prevalence of Lung Cancer Patients with SARS-CoV-2 Infection during the COVID-19 Pandemic. EJMO. 2022; 6(1): 73-82
Corresponding Author: Ahmad Shirinzadeh-Dastgiri